The relevance for TDP1 targeting in anticancer treatment is supported by different studies finding that TDP1 activity is upregulated from normal to tumor tissue in samples from non-small-cell lung cancer patients [6,27] and that loss of TDP1 sensitizes cancer cells to different anticancer drugs [28,29]. Here, TDP1 is linked to cancer.